Organ-Specific Adverse Effects After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2022 Feb 26

PMID 35217973

Authors

Rogini Balachandran

Louise Zinck Mogensen

Peter Christensen

Henriette Vind Thaysen

Lene Hjerrild Iversen

Affiliations

Soon will be listed here.

Citing Articles

Intraoperative hyperthermia is associated with increased acute kidney injury following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective cohort study.

Gao S, Ma J, Kong H, Ma R, Chen S, Wang D Ren Fail. 2024; 46(2):2420835.

PMID: 39494507 PMC: 11536636. DOI: 10.1080/0886022X.2024.2420835.

Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC): Cancer Survivors' Perspective Through In-Depth Interviews.

Falla-Zuniga L, King M, Pawlikowski K, Nikiforchin A, Lopez-Ramirez F, Barakat P Ann Surg Oncol. 2024; 31(10):7122-7132.

PMID: 39060692 DOI: 10.1245/s10434-024-15719-6.

Nutrition Care for the Patient Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.

Figueiroa S, Dourney A Support Line (Chic). 2024; 46(1):2-10.

PMID: 38586177 PMC: 10996839.

Biopsychosocial Late Effects After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases from Colorectal and Appendiceal Cancer: A National Prospective Cohort Study.

Balachandran R, Thaysen H, Christensen P, Zachariae R, Iversen L Ann Surg Oncol. 2023; 31(3):1959-1969.

PMID: 38127212 PMC: 10838225. DOI: 10.1245/s10434-023-14618-6.

References

Harmon R, Sugarbaker P . Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005; 2(1):3. PMC: 549516. DOI: 10.1186/1477-7800-2-3. View

Iversen L, Rasmussen P, Hagemann-Madsen R, Laurberg S . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience. Colorectal Dis. 2013; 15(7):e365-72. DOI: 10.1111/codi.12185. View

Mirnezami R, Mehta A, Chandrakumaran K, Cecil T, Moran B, Carr N . Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014; 111(8):1500-8. PMC: 4200082. DOI: 10.1038/bjc.2014.419. View

Narasimhan V, Tan S, Kong J, Pham T, Michael M, Ramsay R . Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis. Colorectal Dis. 2020; 22(11):1482-1495. DOI: 10.1111/codi.15003. View

Leimkuhler M, Hentzen J, Hemmer P, Been L, van Ginkel R, Kruijff S . Systematic Review of Factors Affecting Quality of Life After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2020; 27(10):3973-3983. PMC: 7471142. DOI: 10.1245/s10434-020-08379-9. View

Chua T, Yan T, Saxena A, Morris D . Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009; 249(6):900-7. DOI: 10.1097/SLA.0b013e3181a45d86. View

Glehen O, Kwiatkowski F, Sugarbaker P, Elias D, Levine E, de Simone M . Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004; 22(16):3284-92. DOI: 10.1200/JCO.2004.10.012. View

Gomez Portilla A, Barrios P, Rufian S, Camps B, Bretcha P, Gonzalez Bayon L . Management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Eur J Surg Oncol. 2006; 32(6):628-31. DOI: 10.1016/j.ejso.2006.03.027. View

van Leeuwen B, Graf W, Pahlman L, Mahteme H . Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol. 2007; 15(3):745-53. DOI: 10.1245/s10434-007-9700-5. View

10.

Franko J, Shi Q, Meyers J, Maughan T, Adams R, Seymour M . Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016; 17(12):1709-1719. DOI: 10.1016/S1470-2045(16)30500-9. View

11.

Piso P, Glockzin G, von Breitenbuch P, Popp F, Dahlke M, Schlitt H . Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. J Surg Oncol. 2009; 100(4):317-20. DOI: 10.1002/jso.21327. View

12.

Shan L, Saxena A, Shan B, Morris D . Quality of life after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis: A systematic review and meta-analysis. Surg Oncol. 2014; 23(4):199-210. DOI: 10.1016/j.suronc.2014.10.002. View

13.

Seretis C, Youssef H . Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review. Eur J Surg Oncol. 2014; 40(12):1605-13. DOI: 10.1016/j.ejso.2014.08.477. View

14.

Tricco A, Lillie E, Zarin W, OBrien K, Colquhoun H, Levac D . PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018; 169(7):467-473. DOI: 10.7326/M18-0850. View

15.

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View

16.

Albertsmeier M, Hauer A, Niess H, Werner J, Graeb C, Angele M . Quality of life in peritoneal carcinomatosis: a prospective study in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Dig Surg. 2014; 31(4-5):334-40. DOI: 10.1159/000369259. View

17.

Alves S, Mohamed F, Yadegarfar G, Youssef H, Moran B . Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Eur J Surg Oncol. 2010; 36(12):1156-61. DOI: 10.1016/j.ejso.2010.09.004. View

18.

Bayat Z, Taylor E, Bischof D, McCart J, Govindarajan A . Impairments in Bowel Function, Social Function and Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2019; 27(1):124-131. DOI: 10.1245/s10434-019-07385-w. View

19.

Chia C, Tan G, Lim C, Soo K, Teo M . Prospective Quality of Life Study for Colorectal Cancer Patients with Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2016; 23(9):2905-13. DOI: 10.1245/s10434-016-5203-6. View

20.

Dodson R, McQuellon R, Mogal H, Duckworth K, Russell G, Votanopoulos K . Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2016; 23(Suppl 5):772-783. PMC: 5391836. DOI: 10.1245/s10434-016-5547-y. View